Diphenhydramine Should Not Be Used Regularly as a Sleep Aid
The American Academy of Sleep Medicine explicitly recommends AGAINST using diphenhydramine for treating chronic insomnia, and regular use carries significant risks including cognitive impairment, next-day sedation, anticholinergic effects, and potential worsening of sleep quality. 1
Why Diphenhydramine Is Not Recommended
The 2017 AASM clinical practice guideline evaluated diphenhydramine at 50 mg doses and found it provides minimal benefit compared to placebo:
- Sleep latency improved by only 8 minutes (not clinically meaningful)
- Total sleep time increased by only 12 minutes
- No improvement in quality of sleep 1
These trivial benefits do not justify the substantial risks associated with regular use.
Specific Risks of Regular Diphenhydramine Use
Cognitive Impairment
Diphenhydramine causes measurable cognitive dysfunction that persists well beyond the perceived sedative effect. Studies demonstrate:
- Impaired divided attention, working memory, speed, and vigilance 2
- Cognitive impairment lasting up to 2 hours after a single dose 3
- In older adults without dementia, regular diphenhydramine use is significantly associated with worse cognitive performance on mental status testing 4
Next-Day Residual Effects
PET scan studies reveal that diphenhydramine occupies 44.7% of brain histamine H₁ receptors the morning after nighttime dosing, creating a measurable "hangover effect" even when patients don't subjectively feel drowsy 5. This creates particular danger for:
- Morning driving impairment
- Workplace performance deficits
- Risk of accidents and errors 2
Anticholinergic Toxicity
The FDA label explicitly warns against use in patients with:
- Glaucoma
- Chronic bronchitis or emphysema
- Urinary retention from enlarged prostate 6
Regular anticholinergic exposure carries additional long-term risks that observational studies have linked to dementia, though this relationship requires cautious interpretation 7.
Sleep Architecture Disruption
Paradoxically, chronic diphenhydramine use actually degrades sleep quality. Recent research in both normal and Alzheimer's disease model mice showed that chronic diphenhydramine:
- Fragments NREM2 sleep (the restorative sleep stage)
- Increases inappropriate daytime drowsiness
- Does not improve underlying sleep deficits 8
Tolerance Development
Patients rapidly develop tolerance to diphenhydramine's sedative effects, requiring escalating doses that increase toxicity risk without improving efficacy.
Additional Safety Concerns
- Marked drowsiness requiring avoidance of alcohol and caution with driving/machinery 6
- Paradoxical excitability, especially in children 6
- Increased risk of falls, confusion, and memory loss in older adults 7
- Association with fractures, motor vehicle accidents, and daytime somnolence in observational studies 7
Critical Pitfall to Avoid
Do not assume that over-the-counter status means diphenhydramine is safe for regular use. The AASM guideline specifically evaluated and rejected diphenhydramine despite its widespread availability, based on poor efficacy and concerning safety profile 1.
What to Recommend Instead
For chronic insomnia, the AASM guideline supports:
- Eszopiclone, zolpidem, or suvorexant for pharmacologic management (though these also have limitations) 1
- Cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment
- Addressing underlying causes of insomnia rather than chronic sedative use
For acute, short-term insomnia in otherwise healthy adults, one recent expert consensus suggests diphenhydramine may be acceptable 9, but this contradicts the higher-quality AASM guideline and should not be extrapolated to regular use.
Bottom Line for Clinical Practice
Patients using diphenhydramine regularly as a sleep aid should be counseled to discontinue it. The combination of minimal efficacy (8-12 minute improvements), no improvement in sleep quality, significant cognitive impairment, next-day sedation with 45% receptor occupancy, and anticholinergic risks makes regular diphenhydramine use inadvisable for any patient population 1, 5, 4. This is particularly critical in older adults where cognitive and fall risks are amplified 4.